Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors

Future Medicinal Chemistry

Volumn 3, Issue 4, 2011, Pages 415-424

  Schneider, Gisbert ^a   Geppert, Tim ^a   Hartenfeller, Markus ^a   Reisen, Felix ^a   Klenner, Alexander ^a   Reutlinger, Michael ^a   Hähnke, Volker ^a   Hiss, Jan A ^a   Zettl, Heiko ^a   Keppner, Sarah ^b   Spadienkuch, Birgit ^b   Schneider, Petra ^a  

^a ETH ZURICH   (Switzerland)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; NUCLEOTIDE; PHOSPHOTRANSFERASE INHIBITOR; POLO LIKE KINASE 1; POLO LIKE KINASE 1 INHIBITOR; POLO LIKE KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; THYMIDINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER AIDED DESIGN; COMPUTER BASED DE NOVO DESIGN; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; IN VITRO STUDY; LIGAND BINDING; MOLECULAR DOCKING; NUCLEOTIDE BINDING SITE; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ARTIFICIAL INTELLIGENCE; BINDING SITES; CELL CYCLE PROTEINS; COMPUTER SIMULATION; COMPUTER-AIDED DESIGN; DRUG DESIGN; LIGANDS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953672431     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.11.8     Document Type: Article

References (69)

1. Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov. 4, 649-663 (2005). (Pubitemid 41149759)
2. Hubbard RE, Chen I, Davis B. Informatics and modeling challenges in fragment-based drug discovery. Curr. Opin. Drug Discov. Devel. 10, 289-297 (2007). (Pubitemid 46800223)
3. Mauser H, Guba W. Recent developments in de novo design and scaffold hopping. Curr. Opin. Drug Discov. Devel. 11, 365-374 (2008). (Pubitemid 351572446)
4. Hartenfeller M, Schneider G. De novo drug design. Methods Mol. Biol. 672, 299-323 (2011).
5. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358-364 (2006). (Pubitemid 43936934)
6. Akritopoulou-Zanze I, Hajduk PJ. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov. Today 14, 291-297 (2009).
7. Mol CD, Fabbro D, Hosfeld DJ. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. Curr. Opin. Drug Discov. Devel. 7, 639-648 (2004). (Pubitemid 39329866)
8. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942 (2000).
9. Pargellis C, Tong L, Churchill L et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9, 268-272 (2002). (Pubitemid 34289898)
10. Wan PT, Garnett MJ, Roe SM et al. Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004). (Pubitemid 38410730)
11. Manley PW, Bold G, Brüggen J et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta 1697, 17-27 (2004). (Pubitemid 38326758)
12. Cumming JG, McKenzie CL, Bowden SG et al. Novel, potent and selective anilino quinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg Med. Chem. Lett. 14, 5389-5394 (2004). (Pubitemid 39359133)
13. Heron NM, Anderson M, Blowers DP et al. SAR and inhibitor complex structure determination of a novel class of potent and specifc Aurora kinase inhibitors. Bioorg Med. Chem. Lett. 16, 1320-1323 (2006). (Pubitemid 43143015)
14. Klebe G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov. Today 11, 580-594 (2006).
15. Langdon S, Ertl P, Brown N. Bioisosteric replacement and scaffold hopping in lead generation and optimization. Mol. Inf. 29, 366-385 (2010).
16. Kufareva I, Abagyan R. Type-II kinase inhibitor docking, screening, and profling using modifed structures of active kinase states. J. Med. Chem. 51, 7921-7932 (2008).
17. Schneider G, Lee ML, Stahl M, Schneider P. De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks. J. Comput. Aided Mol. Des. 14, 487-494(2000). (Pubitemid 30386823)
18. Lewell XQ, Judd DB, Watson SP, Hann MM. RECAP-retrosynthetic combinatorial ana lysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry J. Chem. Inf. Comput. Sci. 38, 511-522 (1998). (Pubitemid 128594467)
19. Bohacek RS, McMartin C, Guida WC. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 16, 3-50 (1996). (Pubitemid 26037075)
20. Fink T, Bruggesser H, Reymond JL. Virtual exploration of the small-molecule chemical universe below 160 Daltons. Angew. Chem. Int. Ed. Engl. 44, 1504-1508 (2005). (Pubitemid 40460043)
21. Ogata K, Isomura T, Yamashita H, Kubodera H. A quantitative approach to the estimation of chemical space from a given geometry by the combination of atomic species. QSAR Comb. Sci. 26, 596-607 (2007). (Pubitemid 46938089)
22. Rarey M, Stahl M. Similarity searching in large combinatorial chemistry spaces. J. Comput. Aided Mol. Des. 15, 497-520 (2001). (Pubitemid 32680852)
23. Rupp M, Proschak E, Schneider G. Kernel approach to molecular similarity based on iterative graph similarity. J. Chem. Inf. Model. 47, 2280-2286 (2007). (Pubitemid 350275094)
24. Rupp M, Schroeter T, Steri R et al. From machine learning to natural product derivatives that selectively activate transcription factor PPARγ. Chem Med Chem 5, 191-194 (2010).
25. Keppner S, Proschak E, Schneider G, Spänkuch B. Identifcation and validation of a potent type II inhibitor of inactive polo-like kinase 1. Chem Med Chem 4, 1806-1809 (2009).
26. Keppner S, Proschak E, Kaufmann M, Strebhardt K, Schneider G, Spänkuch B. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle 9, 761-773 (2010).
27. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat. Rev. Drug Discov. 9, 643-660 (2010).
28. Schneider P, Schneider G. Collection of bioactive reference compounds for focused library design. QSAR Comb. Sci. 22, 713-718 (2003). (Pubitemid 37391067)
29. Berman HM, Westbrook J, Feng Z et al. The Protein Data Bank. Nucleic Acids Res. 28, 235-242 (2000). (Pubitemid 30047768)
30. Schneider G, Neidhart W, Giller T, Schmid G. 'Scaffold-Hopping' by topological pharmacophore search: a contribution to virtual screening. Angew. Chem. Int. Ed. Engl. 38, 2894-2896 (1999). (Pubitemid 29479958)
31. Schneider G, Clément-Chomienne O, Hilfger L et al. Virtual screening for bioactive molecules by evolutionary de novo design. Angew. Chem. Int. Ed. Engl. 39, 4130-4133 (2000).
32. Schüller A, Suhartono M, Fechner U et al. The concept of template-based de novo design from drug-derived molecular fragments and its application to TAR RNA. J. Comput. Aided Mol. Des. 22, 59-68 (2008). (Pubitemid 351247979)
33. Schneider G, Hartenfeller M, Reutlinger M, Tanrikulu Y, Proschak E, Schneider P. Voyages to the (un)known: adaptive design of bioactive compounds. Trends Biotechnol. 27, 18-26 (2009).
34. Heerding DA, Safanov IG, Verma SK. Small molecule inhibitors of AKT/PKB kinase as a strategy for treating cancer. Annu. Rep. Med. Chem. 42, 365-376 (2007).
35. Martin JA, Lambert RW, Merrett JH et al. Nucleoside analogues as highly potent and selective inhibitors of herpes simplex virus thymidine kinase. Bioorg Med. Chem. Lett. 11, 1655-1658 (2001). (Pubitemid 32568290)
36. Bienfait B, Gasteiger J. Checking the projection display of multivariate data with colored graphs. J. Mol. Graph. Model. 15, 203-215, 254-258 (1997). (Pubitemid 28139450)
37. Oprea TI, Gottfries J. Chemography: the art of navigating in chemical space. J. Comb. Chem. 3, 157-166 (2001). (Pubitemid 33614499)
38. Fodor IK. A survey of dimension reduction techniques. LLNL technical report, UCRL-ID-148494 June 2002.
39. Schneider P, Tanrikulu Y, Schneider G. Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing. Curr. Med. Chem. 16, 258-266 (2009).
40. Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 245, 43-53 (1995).
41. Kothe M, Kohls D, Low S et al. Structure of the catalytic domain of human polo-like kinase 1. Biochemistry 46, 5960-5971 (2007). (Pubitemid 46799158)
42. Eswar N, Webb B, Marti-Renom MA et al. Comparative protein structure modeling using MODELLER. Curr. Protoc Bioinf. 5.6.1-5.6.30 (2006).
43. Mooij WTM, Verdonk ML. General and targeted statistical potentials for protein-ligand interactions. Proteins 61, 272-287 (2005). (Pubitemid 41429135)
44. Weisel M, Proschak E, Schneider G. PocketPicker: ana lysis of ligand binding sites with shape descriptors. Chem. Cent. J. 1, 7 (2007).
45. Reisen F, Weisel M, Kriegl JM, Schneider G. Self-organizing fuzzy graphs for structure-based comparison of protein pockets. J. Proteome Res. 9, 6498-6510 (2010).
46. Wang R, Fang X, Lu Y, Yang CY, Wang S. The PDBbind database: methodologies and updates. J. Med. Chem. 48, 4111-4119 (2005). (Pubitemid 40800619)
47. Schmitt S, Kuhn D, Klebe G. A new method to detect related function among proteins independent of sequence and fold homology J. Mol. Biol. 323, 387-406 (2002). (Pubitemid 35283699)
48. Zhao K, Harshaw R, Chai X, Marmorstein R. Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD(+)-dependent Sir2 histone/protein deacetylases. Proc Natl. Acad. Sci. USA 101, 8563-8568 (2004). (Pubitemid 38745810)
49. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42, 260-266 (1999). (Pubitemid 29069861)
50. Apostolopoulos V, Yu M, Corper AL et al. Crystal structure of a non-canonical low-affnity peptide complexed with MHC class I: a new approach for vaccine design. J. Mol. Biol. 318, 1293-1305 (2002). (Pubitemid 34753998)
51. Haapalainen AM, van Aalten DM, Meriläinen G et al. Crystal structure of the liganded SCP-2-like domain of human peroxisomal multifunctional enzyme type II at 1.75 Å resolution. J. Mol. Biol. 313, 1127-1138 (2001). (Pubitemid 33081906)
52. Ghosh AK, Kumaragurubaran N, Hong L et al. Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (ß-secretase) inhibitors. J. Am. Chem. Soc 128, 5310-5311 (2006).
53. Parkkila S, Innocenti A, Kallio H, Hilvo M, Scozzafava A, Supuran CT. The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian α-carbonic anhydrase isoforms. Bioorg. Med. Chem. Lett. 19, 4102-4106 (2009).
54. Lénárt P, Petronczki M, Steegmaier M. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr. Biol. 17, 304-315 (2007).
55. Steegmaier M, Hoffmann M, Baum A et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. 17, 316-322 (2007). (Pubitemid 46241881)
56. Spänkuch-Schmitt B, Wolf G et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 21, 3162-3171 (2002). (Pubitemid 34548087)
57. Jorgensen WL. Effcient drug lead discovery and optimization. Acc. Chem. Res. 42, 724-733 (2009).
58. Mestres J. Computational chemogenomics approaches to systematic knowledge-based drug discovery. Curr. Opin. Drug Discov. Devel. 7, 304-313 (2004). (Pubitemid 44120947)
59. Schneider G, Tanrikulu Y, Schneider P. Self-organizing molecular fngerprints: a ligand-based view on drug-like chemical space and off-target prediction. Future Med. Chem. 1, 213-218 (2009).
60. Kuhn D, Weskamp N, Hüllermeier E, Klebe G. Functional classifcation of protein kinase binding sites using Cavbase. Chem Med Chem 2, 1432-1447 (2007).
61. Kinnings SL, Jackson RM. Binding site similarity ana lysis for the functional classifcation of the protein kinase family J. Chem. Inf. Model. 42, 318-329 (2009).
62. Milletti F, Vulpetti A. Predicting polypharmacology by binding site similarity: from kinases to the protein universe. J. Chem. Inf. Model. 50, 1418-1431 (2010).
63. Wassermann AM, Wawer M, Bajorath J. Activity landscape representations for structure-activity relationship ana lysis. J. Med. Chem. 53, 8209-8223 (2010).
64. Medina-Franco JL, Martínez-Mayorga K, Bender A et al. Characterization of activity landscapes using 2D and 3D similarity methods: consensus activity cliffs. J. Chem. Inf. Model. 49, 477-491 (2009).
65. Campbell SJ, Gaulton A, Marshall J et al. Visualizing the drug target landscape. Drug Discov. Today 15, 3-15 (2010).
66. Davey S. Chemistry: thinking outside the fask. Nature 458, 294 (2009).
67. Schneider G. Virtual screening: an endless staircase? Nat. Rev. Drug Discov. 9, 273-276 (2010).
68. Agrafotis DK. Stochastic algorithms for maximizing molecular diversity. J. Chem. Inf. Comp. Sci. 37, 841-851 (1997).
69. Agrafotis DK, Xu H, Zhu F, Banyopadhyay D, Liu P. Stochastic proximity embedding: methods and applications. Mol. Inf. 29, 758-770 (2009).